Fresenius Kabi launches Velcade alternative
Fresenius Kabi has introduced its alternative of Takeda Oncology’s Velcade (bortezomib for injection). The Lake Zurich, Ill.-based company said that this addition to its oncology offerings is the first available alternative for intravenous use.
Fresenius Kabi’s product is available in a single-dose vial that contains 3.5 mg of lyophilized powder.
“Fresenius Kabi bortezomib is a cost-efficient product alternative for our customers and the patients they treat,” Fresenius Kabi USA president and CEO John Ducker said. “We are proud to offer an expansive oncology portfolio and will continue to develop these essential medicines”
Fresenius Kabi's product is indicated to treat patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior treatment.
According to Takeda’s quarterly filings, Velcade has had U.S. sales of $60.2 million for the first two quarters of its fiscal year 2017. For the full fiscal year 2016, Takeda reported $112.9 million in U.S. sales for Velcade.
Fresenius Kabi’s product is available in a single-dose vial that contains 3.5 mg of lyophilized powder.
“Fresenius Kabi bortezomib is a cost-efficient product alternative for our customers and the patients they treat,” Fresenius Kabi USA president and CEO John Ducker said. “We are proud to offer an expansive oncology portfolio and will continue to develop these essential medicines”
Fresenius Kabi's product is indicated to treat patients with multiple myeloma and patients with mantle cell lymphoma who have received at least one prior treatment.
According to Takeda’s quarterly filings, Velcade has had U.S. sales of $60.2 million for the first two quarters of its fiscal year 2017. For the full fiscal year 2016, Takeda reported $112.9 million in U.S. sales for Velcade.